Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYRWF Ayr Wellness	$0.15 -3.2%	$0.19	$0.09 ▼ $2.60	$17.43M	1.82	299,422 shs	65,103 shs
DRRX DURECT	$0.54 -4.0%	$0.61	$0.48 ▼ $1.74	$16.77M	0.64	80,382 shs	87,387 shs
HOTH Hoth Therapeutics	$1.35 +0.4%	$1.13	$0.58 ▼ $3.80	$17.77M	0.67	3.71 million shs	141,515 shs
IPCIF Intellipharmaceutics International		$0.00	$0.00 ▼ $0.15	$4.96M	1.53	12,042 shs	N/A

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYRWF Ayr Wellness	+3.33%	-26.19%	-7.79%	-9.88%	-92.86%
DRRX DURECT	+6.11%	-13.18%	-10.92%	-24.55%	-58.63%
HOTH Hoth Therapeutics	0.00%	-6.29%	+2.29%	+70.14%	+44.09%
IPCIF Intellipharmaceutics International	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYRWF Ayr Wellness	1.6229 of 5 stars	3.3	3.0	0.0	0.0	0.0	0.0	1.3
DRRX DURECT	1.212 of 5 stars	0.0	3.0	0.0	4.4	3.3	0.0	0.0
HOTH Hoth Therapeutics	3.2725 of 5 stars	3.6	5.0	0.0	0.0	3.8	0.0	0.6
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYRWF Ayr Wellness	2.50	Moderate Buy	$3.00	1,900.00% Upside
DRRX DURECT	2.00	Hold	N/A	N/A
HOTH Hoth Therapeutics	3.25	Buy	$4.00	197.40% Upside
IPCIF Intellipharmaceutics International	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPCIF, DRRX, AYRWF, and HOTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYRWF Ayr Wellness	$463.63M	0.04	N/A	N/A	$3.14 per share	0.05
DRRX DURECT	$2.03M	8.26	N/A	N/A	$0.29 per share	1.86
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
IPCIF Intellipharmaceutics International	$660K	0.00	N/A	N/A	($0.32) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYRWF Ayr Wellness	-$359.31M	-$3.26	N/A	N/A	N/A	-77.50%	-31.73%	-11.73%	N/A
DRRX DURECT	-$8.32M	-$0.15	N/A	N/A	N/A	-91.54%	-267.36%	-64.00%	8/12/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
IPCIF Intellipharmaceutics International	-$2.89M	-$0.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IPCIF, DRRX, AYRWF, and HOTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	DRRX DURECT	-$0.13	N/A	N/A	N/A	$0.32 million	N/A
8/8/2025	N/A	HOTH Hoth Therapeutics	-$0.27	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYRWF Ayr Wellness	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYRWF Ayr Wellness	1.10	1.60	0.57
DRRX DURECT	N/A	1.23	1.22
HOTH Hoth Therapeutics	N/A	15.09	15.08
IPCIF Intellipharmaceutics International	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYRWF Ayr Wellness	0.91%
DRRX DURECT	28.03%
HOTH Hoth Therapeutics	7.08%
IPCIF Intellipharmaceutics International	N/A

Insider Ownership

Company	Insider Ownership
AYRWF Ayr Wellness	8.10%
DRRX DURECT	3.20%
HOTH Hoth Therapeutics	6.92%
IPCIF Intellipharmaceutics International	1.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYRWF Ayr Wellness	2,440	116.19 million	106.77 million	Not Optionable
DRRX DURECT	80	31.04 million	30.05 million	Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
IPCIF Intellipharmaceutics International	10	33.09 million	32.51 million	Not Optionable

IPCIF, DRRX, AYRWF, and HOTH Headlines

Recent News About These Companies

Intellipharmaceutics Announces Downgrade to OTC Expert Market

June 14, 2024 | accesswire.comA

Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan

March 13, 2024 | accesswire.comA

Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Cease Trade Order

March 6, 2024 | finanznachrichten.de

Intellipharmaceutics Announces Cease Trade Order

March 6, 2024 | accesswire.comA

Intellipharmaceutics International Inc. (IPCI.TO)

February 28, 2024 | ca.finance.yahoo.com

Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form

February 26, 2024 | accesswire.comA

Intellipharmaceutics International Inc. Announces Stock Option Grant

February 8, 2024 | finance.yahoo.com

Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange

January 2, 2024 | finance.yahoo.com

Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2023 Results

October 16, 2023 | finanznachrichten.de

Intellipharmaceutics Announces Second Quarter 2023 Results

July 14, 2023 | finance.yahoo.com

Closing Bell: Intellipharmaceutics International Inc up on Monday (IPCI)

June 27, 2023 | theglobeandmail.com

Closing Bell: Intellipharmaceutics International Inc up on Friday (IPCI)

June 10, 2023 | theglobeandmail.com

Intellipharmaceutics International reports FY 2022 and Q1 2023 results

June 6, 2023 | msn.com

Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results

June 6, 2023 | finance.yahoo.com

Jim Cramer -- International Paper, United Technologies Looking More Attractive

May 10, 2023 | thestreet.com

Closing Bell: Intellipharmaceutics International Inc flat on Tuesday (IPCI)

April 12, 2023 | theglobeandmail.com

Closing Bell: Intellipharmaceutics International Inc flat on Thursday (IPCI)

April 11, 2023 | theglobeandmail.com

IPCIF Intellipharmaceutics International Inc.

March 17, 2023 | seekingalpha.com

Intellipharmaceutics Announces Cease Trade Order

March 7, 2023 | finance.yahoo.com

Intellipharmaceutics Announces its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form and its Management Cease Trade Order Application

February 6, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPCIF, DRRX, AYRWF, and HOTH Company Descriptions

Ayr Wellness OTCMKTS:AYRWF

$0.15 -0.01 (-3.23%)

As of 12:52 PM Eastern

Ayr Wellness Inc. operates as a vertically-integrated multi-state cannabis operator that cultivates, manufactures, and retails cannabis products and branded cannabis packaged goods. It owns and operates a chain of cannabis retail stores under AYR, Liberty Health Sciences, and The Dispensary brand names. The company was formerly known as Ayr Strategies Inc. and changed its name to Ayr Wellness Inc. in February 2021. Ayr Wellness Inc. was incorporated in 2017 and is headquartered in Miami, Florida.

DURECT NASDAQ:DRRX

$0.54 -0.02 (-3.98%)

As of 12:59 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Hoth Therapeutics NASDAQ:HOTH

$1.34 +0.01 (+0.37%)

As of 01:19 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Intellipharmaceutics International OTCMKTS:IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time